Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 37, 2759-2763, August 1, 1977]
© 1977 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Caldwell, W. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Caldwell, W. L.

The Role of Irradiation in the Management of Clinical Stage B1 (Grades II and III) and Stages B2 and C Bladder Cancer1

William L. Caldwell

Division of Radiation Oncology, Department of Human Oncology, University of Wisconsin Hospitals, Madison, Wisconsin 53706

For patients with high-grade tumors infiltrating the superficial bladder wall musculature or with tumors of any grade invading deep muscle or the perivesical space, the evidence is now quite solid that integrated treatment with irradiation and cystectomy (or a lesser resection in rare, selected cases) results in a significantly higher survival rate than does either approach alone.

Several questions still remain unanswered regarding integrated therapy, however. (a) Should the irradiation be done preoperatively or postoperatively? The pros and cons of each approach are discussed. (b) What is the appropriate dose of irradiation? A dose that has a high probability of eradicating minimal disease in lymph nodes or elsewhere in the pelvis (4600 rads/23 treatments/4.5 weeks to 5040 rads/28 treatments/5.5 weeks) is recommended. (c) What volume should be irradiated? Since the irradiation is intended to control disease not removed at operation and the lymph nodes in the pelvis are at risk, whole pelvis treatment extending from the bottom of the obturator foramen to the sacral promontory (bifurcation of the common iliac artery) is used.

With integrated therapy patients now most frequently succumb because of disseminated disease, not detected at the time of such treatment. Effective adjuvant chemotherapy regimens would presumably permit a further improvement in survival.

1 Presented at the National Bladder Cancer Conference, November 28 to December 1, 1976, Miami Beach, Fla. Work supported in part by National Cancer Institute Grant CA19278, "Multidisciplinary Program in Radiation Oncology."







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1977 by the American Association for Cancer Research.